Hypersensitivity vasculitis associated with leuprolide (Lupron).
Level 4 - case-series / case-control
Single clinical case report
PubMed 20470239 · doi:10.3109/15569527.2010.487505
What was done
A case report documenting an adverse reaction in a patient who received leuprolide (Lupron), a synthetic GnRH analog, for the treatment of prostate cancer.
What was found
The abstract reports a single case of hypersensitivity vasculitis (serum sickness) in a patient receiving leuprolide. The abstract provides no specific patient characteristics, clinical values, or quantitative outcome measures.
Why it matters
This constitutes the first reported case of serum sickness associated with leuprolide, highlighting a rare potential hypersensitivity reaction for clinicians administering GnRH analogs.
Limits
As a single-patient case report (n = 1), it cannot establish incidence, definitive causality, or risk factors. Detailed clinical course, diagnostic criteria, and laboratory numbers are omitted from the abstract.
Cited by
- supports Lupron was introduced in 1985 as a peptide designed to shut down testosterone production for prostate cancer patients.